Ergomed Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	1.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Ergomed non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Miroslav Reljanovic	Founder & Executive Chairman	5.9yrs	UK£964.30k	17.98% € 102.0m
Michael Spiteri	Chief Transformation & Technology Officer	less than a year	UK£52.77k	Nessun dato
Jonathan Curtain	CFO & Executive Director	less than a year	Nessun dato	Nessun dato
Michael Forstner	Head of Risk Management & Pharmacoepidemiology	5.1yrs	Nessun dato	Nessun dato
Sally Amanuel	President of PrimeVigilance	no data	Nessun dato	Nessun dato
Gordana Tonkovic	President of Clinical Research	no data	Nessun dato	Nessun dato
Ronel Steyn	Senior Vice President of Global Development	1.6yrs	Nessun dato	Nessun dato
Keith Byrne	Senior Vice-President of Capital Markets & Strategy	1.4yrs	Nessun dato	Nessun dato
Joanne Bletcher	Company Secretary	no data	Nessun dato	Nessun dato

1.5yrs

Durata media

Gestione esperta: Il team dirigenziale di 2EM non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Miroslav Reljanovic	Founder & Executive Chairman	5.9yrs	UK£964.30k	17.98% € 102.0m
Jonathan Curtain	CFO & Executive Director	less than a year	Nessun dato	Nessun dato
Mark Enyedy	Independent Non-Executive Director	2yrs	UK£52.72k	Nessun dato
Llew Keltner	Independent Non-Executive Director	2.2yrs	UK£52.72k	Nessun dato
Anne Michelle Whitaker	Independent Non-Executive Director	less than a year	UK£27.89k	Nessun dato
John Dawson	Senior Independent Director	1.3yrs	UK£49.15k	Nessun dato

1.6yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 2EM non è considerato esperto (durata media del mandato 1.6 anni), il che suggerisce un nuovo consiglio.

Ergomed Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Ergomed plc, Annual General Meeting, Jun 22, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Ergomed plc, Annual General Meeting, Jun 22, 2023

Full year 2022 earnings released: EPS: UK£0.30 (vs UK£0.26 in FY 2021)

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Now 21% undervalued after recent price drop

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Ergomed plc, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Now 21% undervalued

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Investor sentiment improved over the past week

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Investor sentiment improved over the past week

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Investor sentiment improved over the past week

Non-Executive Director has left the company

Investor sentiment improved over the past week

Full year 2020 earnings released

New 90-day high: €14.15

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: €13.40

New 90-day high: €12.10

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

New 90-day high: €9.76

New 90-day high: €9.58

New 90-day high - €7.68

New 90-day high - €6.86

Ergomed plc to Report First Half, 2020 Results on Sep 22, 2020

New 90-day high - €6.60

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media